Apr. 4 at 4:43 PM
$REPL
While FDA decisions on resubmissions after a CRL carry inherent uncertainty (especially when the original pivotal data came from a single-arm study), the targeted addressing of prior concerns, alignment with an ongoing confirmatory trial, and the clear unmet need in a life-threatening condition collectively tilt toward a plausible path to approval on the April 10, 2026 target date. This remains a regulatory binary event with potential for extension or advisory committee input.
In summary, the investment carries high risk—suitable primarily for portfolios that can tolerate substantial near-term volatility or outright capital loss. The April 10, 2026 decision represents a pivotal inflection with clear potential for material re-rating (positive) or de-rating (negative), driven predominantly by regulatory interpretation of existing evidence rather than new clinical data.
Investors should weigh position sizing accordingly and consider the possibility of post-PDUFA dilution.
